Long-Term Toxicity of High Dose Rate Brachytherapy in Prostate Carcinoma Patients With Inflammatory Bowel Disease

Lehrich, Brandon M.; Moyses, Helen; Kawakubo, Atsushi; Ravera, John; Barnes, Lucy; Mesa, Albert; Tokita, Kenneth

doi:10.1016/j.clon.2019.01.013

Cited by 3 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…reported on patients with prostate cancer and IBD, with 70% receiving a hydrogel rectal spacer at the time of EBRT with HDR-BT boost [ 7 , 23 ]. No patient experienced severe acute or late proctitis or diarrhea [ 11 ]. In our cohort, seven patients received rectal spacers, and no severe GI toxicity was observed.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety of high-dose-rate brachytherapy in patients with prostate cancer and inflammatory bowel disease: A case series

Thomas,

Chen,

Shaheen

et al. 2024

jcb

View full text Add to dashboard Cite

Introduction Inflammatory bowel disease (IBD) is a relative contraindication to external beam radiation therapy (EBRT) for prostate cancer patients due to fear of increased risk of gastrointestinal (GI) toxicity. High-dose-rate (HDR) brachytherapy, capable of minimizing radiation dose to surrounding tissues, is a feasible alternative. Given limited data, this study examined the safety profile of HDR brachytherapy in this setting. Material and methods We conducted a retrospective review of patients with localized prostate cancer and IBD treated with HDR brachytherapy at the University of California San Francisco (UCSF), between 2010 and 2022. Eligibility criteria included biopsy-proven prostate cancer, no distant metastases, absence of prior pelvic radiotherapy, IBD diagnosis, and at least one follow-up visit post-treatment. Results Eleven patients were included, with a median follow-up of 28.7 months. The median dose administered was 2700 cGy (range, 1500-3150 cGy) over 2 fractions (range, 1-3 fractions). Two patients also received EBRT. Rectal spacers (SpaceOAR) were applied in seven patients. All patients experienced acute genitourinary (GU) toxicity, ten of which were grade 1 and one was grade 2. Eight patients experienced late grade 1 GU toxicity, and three patients had late grade 2 GU toxicity. GI toxicities were similarly low-grade, with six grade 1 acute toxicity, no grade 2 or higher acute toxicity, six grade 1 late toxicity, and one late grade 2 GI toxicity. No grade 3 or higher acute or late GI or GU toxicities were reported. Conclusions HDR brachytherapy appears to be a safe and tolerable treatment modality for patients with prostate cancer and IBD, with minimal acute and late GI and GU toxicity. These findings warrant multi-institutional validation due to small sample size.

show abstract

Section: Discussionmentioning

confidence: 99%

“…High-dose-rate brachytherapy (HDR-BT) is a precision-focused alternative that offers excellent local control while limiting dose to surrounding tissues [ 8 , 9 ]. However, data on the safety of HDR-BT in patients with IBD is limited to small retrospective studies or institutional case series [ 10 , 11 ].…”

Section: Purposementioning

confidence: 99%

Safety of high-dose-rate brachytherapy in patients with prostate cancer and inflammatory bowel disease: A case series

Thomas,

Chen,

Shaheen

et al. 2024

jcb

View full text Add to dashboard Cite

show abstract

“…Результаты весьма успешного использования БДС продемонстрированы также в исследованиях, посвященных повторному облучению ПЖ в случае локального прогрессирования процесса после различных вариантов первичного лучевого воздействия (брахитерапии, ДЛТ) [40,41]. Большой интерес представляет работа B. M. Lehrich и соавт., в которой показаны преимущества применения спейсеров при высокомощностной брахитерапии у пациентов с воспалительными заболеваниями прямой кишки [42], ранее рассматривавшимися в качестве относительных ОНКОУРОЛОГИЯ 3'2021 ТОМ 17 CANCER UROLOGY 3'2021 VOL. 17…”

Section: методика применения спейсеров и их характеристикаunclassified

Technologies to reduce radiation toxicity in prostate cancer patients: spacers - a simple and effective solution

Novikov

Новиков

2021

Onkourologiâ

View full text Add to dashboard Cite

The basic principles of the treatment of prostate cancer patients have underwent significant revisions in recent years. Modern radiotherapy techniques, which have demonstrated high efficacy and safety in long-term randomized trials, are beginning to take a leading position in the treatment of prostate cancer in an overwhelming number of clinical scenarios (National Comprehensive Cancer Network, 2021). Despite the obvious successes of radiation oncology, a number of important problems remain unresolved, first of all - the need to reduce the rates of radiation complications. The topographical anatomy of the prostate gland determines the main profiles of post-radiation damage: rectal and genitourinary radiation toxicity. The previous five years have been marked by a significant intensification of research work abroad aimed at clinical testing of a number of biopolymer compositions and products for use as spacers between irradiated structures and normal tissues. The experience has made it possible for the first time to consider the possibility of using spacers in radiotherapy treatment of prostate cancer in the modern recommendations of the European Association of Urology (2021). The analysis of the national literature shows a complete lack of publications on the possibilities of optimizing the radiation treatment of prostate cancer through the use of specers. The purpose of this work was the need to highlight this important and perspective clinical problem.

show abstract

Safety of Radiation Therapy in Patients With Prostate Cancer and Inflammatory Bowel Disease: A Systematic Review

Trotta¹,

Patel²,

Singh³

et al. 2023

Practical Radiation Oncology

View full text Add to dashboard Cite

Long-Term Toxicity of High Dose Rate Brachytherapy in Prostate Carcinoma Patients With Inflammatory Bowel Disease

Cited by 3 publications

References 6 publications

Safety of high-dose-rate brachytherapy in patients with prostate cancer and inflammatory bowel disease: A case series

Safety of high-dose-rate brachytherapy in patients with prostate cancer and inflammatory bowel disease: A case series

Technologies to reduce radiation toxicity in prostate cancer patients: spacers - a simple and effective solution

Safety of Radiation Therapy in Patients With Prostate Cancer and Inflammatory Bowel Disease: A Systematic Review

Contact Info

Product

Resources

About